- Home
- EXEL
EXEL
Exelixis Inc.
as 02-21-2025 4:00pm EST
Exelixis is a biopharmaceutical firm that discovers, develops, and commercializes treatments for cancer. Its lead molecule, cabozantinib, is indicated for the treatment of patients with metastatic medullary thyroid cancer under the name Cometriq and for the treatment of kidney and liver cancer under the name Cabometyx. Exelixis and its partner Roche have also brought Cotellic to market for the treatment of melanoma.
| Founded: | 1994 | Country: | United States |
| Employees: | N/A | City: | ALAMEDA |
| Market Cap: | 9.4B | IPO Year: | 2000 |
| Target Price: | $37.24 | AVG Volume (30 days): | 2.5M |
| Analyst Decision: | Buy | Number of Analysts: | 18 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | 1.76 | EPS Growth: | 170.77 |
| 52 Week Low/High: | $20.14 - $37.59 | Next Earning Date: | 02-11-2025 |
| Revenue: | $2,168,701,000 | Revenue Growth: | 18.49% |
| Revenue Growth (this year): | 5.36% | Revenue Growth (next year): | 10.59% |
Stock Insider Trading Activity of Exelixis Inc. (EXEL)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Beckerle Mary C | EXEL | Director | Feb 14 '25 | Sell | $34.89 | 12,210 | $425,878.38 | 34,262 | |
| Eckhardt Sue Gail | EXEL | Director | Feb 14 '25 | Sell | $35.03 | 11,568 | $405,111.36 | 30,406 | |
| Freire Maria C | EXEL | Director | Feb 14 '25 | Sell | $34.94 | 44,114 | $1,541,343.16 | 91,007 | |
| POSTE GEORGE | EXEL | Director | Feb 14 '25 | Sell | $34.74 | 15,874 | $551,462.76 | 169,020 | |
| Hessekiel Jeffrey | EXEL | EVP & General Counsel | Nov 27 '24 | Sell | $36.67 | 60,000 | $2,200,200.00 | 486,059 |
Latest Exelixis Inc. News
EXEL Breaking Stock News: Dive into EXEL Ticker-Specific Updates for Smart Investing
Simply Wall St.
13 hours ago
Exelixis' (NASDAQ:EXEL) Earnings May Just Be The Starting Point
MT Newswires
a day ago
Exelixis Board Authorizes Additional Share Buyback Program of Up To $500 Million; Shares Advance After Hours
Business Wire
a day ago
Exelixis Announces a Newly Authorized $500 Million Stock Repurchase Program
Zacks
a day ago
Is Exelixis (EXEL) a Solid Growth Stock? 3 Reasons to Think "Yes"
Zacks
a day ago
Are You a Growth Investor? This 1 Stock Could Be the Perfect Pick
MT Newswires
2 days ago
Exelixis Insider Sold Shares Worth $1,541,343, According to a Recent SEC Filing
Argus Research
3 days ago
EXEL: Raising target price to $37.00
Zacks
3 days ago
Exelixis Gains 6.7% Post Q4 Earnings: Is This the Right Time to Buy?
Compare EXEL vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "EXEL Exelixis Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.